Loading
companiesCompany
Agenus
Agenus is a Massachusetts immuno-oncology company developing botensilimab, an Fc-enhanced anti-CTLA-4 antibody, with its anti-PD-1 balstilimab, notably in microsatellite-stable colorectal cancer where checkpoint inhibitors have not worked.
Also called: Agenus Inc.Agenus Inc
Overview
Agenus, based in Lexington, Massachusetts and listed on Nasdaq, develops checkpoint antibodies and cancer vaccines. Its lead combination is botensilimab, a next-generation anti-CTLA-4 antibody with an engineered Fc region, given with balstilimab, an anti-PD-1 antibody, which has shown responses in microsatellite-stable colorectal cancer without liver metastases and other cold tumours; the company has sought accelerated approval and runs registrational trials. OnCo records it as a registry sponsor of phase 3 cancer trials.
Headquarters
Lexington, MA, US
Scorecard
All companies#140of 1244 companies, score 42
- phase 1/2 +4
- targets +4
- modalities +4
- registry trials +30
0 approved, 0 in phase 3, 4 earlier, 2 targets, 218 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 2monoclonal antibody
Botensilimab is an experimental monoclonal antibody from Agenus in phase 2 trials for colorectal cancer, aimed at CTLA-4.
Phase 2Monoclonal antibody
Zalifrelimab is a monoclonal antibody from Nelum Corp, in registered phase 2 trials for pancreatic ductal adenocarcinoma.
Phase 2Monoclonal antibody
Balstilimab is a monoclonal antibody from Agenus Inc., in registered phase 2 trials for colorectal cancer.
Phase 2Oral antiparasitic small molecule (macrocyclic lactone), studied in cancer as an add-on to checkpoint antibodies
Ivermectin · Stromectol
Ivermectin is a worm and parasite medicine that is being tested as an add-on to immunotherapy in two small early trials. No trial has shown that it treats any cancer, and people who have dosed themselves outside a trial have ended up in hospital with seizures or liver damage.
Similar pages
- IdeaMaking microsatellite-stable colorectal cancer immunotherapy-responsive
Shares Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial, Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed, CTLA-4, PD-1.
- TrialThe Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Shares Botensilimab, Balstilimab.
- TrialBAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
Shares Botensilimab, Balstilimab.
- TrialNeoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
Shares Botensilimab, Balstilimab.
- TrialPhase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Shares Botensilimab, Balstilimab.
- TrialTesting the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
Shares Botensilimab, Balstilimab.
- PersonHeinz-Josef Lenz
Shares Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial, CTLA-4, PD-1, Colorectal cancer.
- Key paperIvermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)
Shares Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2), Ivermectin.
cancers
fronts
targets
drugs
Phase 2Monoclonal antibody
Phase 2monoclonal antibody
Phase 2Oral antiparasitic small molecule (macrocyclic lactone), studied in cancer as an add-on to checkpoint antibodies
Ivermectin · Stromectol
Phase 2Monoclonal antibody
trials
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyA Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaA Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerA Study of Evofosfamide in Combination with Zalifrelimab and BalstilimabIvermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver MetastasesRECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerVorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers